21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sphingolipids as critical players in retinal physiology and pathology

      review-article
      1 , , 2 , , 2 , 2 , 1 , , 2 ,
      Journal of Lipid Research
      American Society for Biochemistry and Molecular Biology
      ceramide, sphingosine-1-phosphate, ceramide-1-phosphate, photoreceptor degeneration, age-related macular degeneration, retinitis pigmentosa, ADIPOR1, adiponectin receptor 1, AH, aqueous humor, AMD, age-related macular degeneration, ASAH, N-acyl-sphingosine amidohydrolase, aSMase, acid SMase, BEST1, bestrophin-1, BDNF, brain-derived neurotrophic factor, CDase, ceramidase, Cer, ceramide, CerK, ceramide kinase, CERKL, ceramide kinase-like, CerS, ceramide synthase, CFH, complement factor H, C1P, ceramide 1-phosphate, DHCer, dihydroceramide, DR, diabetic retinopathy, EAU, experimental autoimmune uveoretinitis, GA, geographic atrophy, GalCer, galactosylceramide, GCS, glucosylceramide synthase, GlcCer, glucosylceramide, hBest1, human bestrophin-1, HexCer, hexosylceramide, IOP, intraocular pressure, LacCer, lactosylceramide, Mac Tel, macular telangiectasia, NGF, nerve growth factor, nSMase, neutral sphingomyelinase, OAG, open-angle glaucoma, PARP-1, poly-ADP ribose polymerase 1, PDR, proliferative diabetic retinopathy, PKC, protein kinase C, POAG, primary open-angle glaucoma, RP, retinitis pigmentosa, RPE, retinal pigment epithelium, SMS, SM synthase, Sph, sphingosine, SphK, sphingosine kinase, S1PR, S1P receptor, SPT, serine palmitoyl transferase, VEGF, vascular endothelial growth factor, VMD, vitelliform macular dystrophy

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sphingolipids have emerged as bioactive lipids involved in the regulation of many physiological and pathological processes. In the retina, they have been established to participate in numerous processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Dysregulation of sphingolipids is therefore crucial in the onset and progression of retinal diseases. This review examines the involvement of sphingolipids in retinal physiology and diseases. Ceramide (Cer) has emerged as a common mediator of inflammation and death of neuronal and retinal pigment epithelium cells in animal models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. Sphingosine-1-phosphate (S1P) has opposite roles, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1-phosphate may also contribute to uveitis. Notably, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), preserves neuronal viability and retinal function. These findings underscore the relevance of alterations in the sphingolipid metabolic network in the etiology of multiple retinopathies and highlight the potential of modulating their metabolism for the design of novel therapeutic approaches.

          Related collections

          Most cited references370

          • Record: found
          • Abstract: found
          • Article: not found

          The pathophysiology and treatment of glaucoma: a review.

          Glaucoma is a worldwide leading cause of irreversible vision loss. Because it may be asymptomatic until a relatively late stage, diagnosis is frequently delayed. A general understanding of the disease pathophysiology, diagnosis, and treatment may assist primary care physicians in referring high-risk patients for comprehensive ophthalmologic examination and in more actively participating in the care of patients affected by this condition. To describe current evidence regarding the pathophysiology and treatment of open-angle glaucoma and angle-closure glaucoma. A literature search was conducted using MEDLINE, the Cochrane Library, and manuscript references for studies published in English between January 2000 and September 2013 on the topics open-angle glaucoma and angle-closure glaucoma. From the 4334 abstracts screened, 210 articles were selected that contained information on pathophysiology and treatment with relevance to primary care physicians. The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role. Reduction of intraocular pressure is the only proven method to treat the disease. Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression. Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with positive family history or with suspicious optic nerve head findings for complete ophthalmologic examination. They can improve treatment outcomes by reinforcing the importance of medication adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgeries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The number of people with glaucoma worldwide in 2010 and 2020.

            To estimate the number of people with open angle (OAG) and angle closure glaucoma (ACG) in 2010 and 2020. A review of published data with use of prevalence models. Data from population based studies of age specific prevalence of OAG and ACG that satisfied standard definitions were used to construct prevalence models for OAG and ACG by age, sex, and ethnicity, weighting data proportional to sample size of each study. Models were combined with UN world population projections for 2010 and 2020 to derive the estimated number with glaucoma. There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG. Women will comprise 55% of OAG, 70% of ACG, and 59% of all glaucoma in 2010. Asians will represent 47% of those with glaucoma and 87% of those with ACG. Bilateral blindness will be present in 4.5 million people with OAG and 3.9 million people with ACG in 2010, rising to 5.9 and 5.3 million people in 2020, respectively. Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multiple sclerosis

              Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly, there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing health-related quality of life through advocating wellness, addressing aggravating factors, and managing comorbidities. The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Lipid Res
                J Lipid Res
                Journal of Lipid Research
                American Society for Biochemistry and Molecular Biology
                0022-2275
                1539-7262
                06 February 2021
                2021
                06 February 2021
                : 62
                : 100037
                Affiliations
                [1 ]Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Departamento De Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), Argentine National Research Council (CONICET), Bahía Blanca, Argentina
                [2 ]Departments of Ophthalmology and Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN, USA
                Author notes
                []For correspondence: Nora P. Rotstein; Nawajes Mandal inrotste@ 123456criba.edu.ar nmandal@ 123456uthsc.edu
                [‡]

                These authors contributed equally to this work.

                Article
                S0022-2275(21)00017-1 100037
                10.1194/jlr.TR120000972
                7933806
                32948663
                c8618444-69f2-47e2-b291-5a3f610327c8
                © 2021 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 11 June 2020
                : 4 September 2020
                Categories
                Thematic Review Series
                Thematic Review Series: Seeing 2020: Lipids and Lipid-Soluble Molecules in the Eye

                Biochemistry
                ceramide,sphingosine-1-phosphate,ceramide-1-phosphate,photoreceptor degeneration,age-related macular degeneration,retinitis pigmentosa,adipor1, adiponectin receptor 1,ah, aqueous humor,amd, age-related macular degeneration,asah, n-acyl-sphingosine amidohydrolase,asmase, acid smase,best1, bestrophin-1,bdnf, brain-derived neurotrophic factor,cdase, ceramidase,cer, ceramide,cerk, ceramide kinase,cerkl, ceramide kinase-like,cers, ceramide synthase,cfh, complement factor h,c1p, ceramide 1-phosphate,dhcer, dihydroceramide,dr, diabetic retinopathy,eau, experimental autoimmune uveoretinitis,ga, geographic atrophy,galcer, galactosylceramide,gcs, glucosylceramide synthase,glccer, glucosylceramide,hbest1, human bestrophin-1,hexcer, hexosylceramide,iop, intraocular pressure,laccer, lactosylceramide,mac tel, macular telangiectasia,ngf, nerve growth factor,nsmase, neutral sphingomyelinase,oag, open-angle glaucoma,parp-1, poly-adp ribose polymerase 1,pdr, proliferative diabetic retinopathy,pkc, protein kinase c,poag, primary open-angle glaucoma,rp, retinitis pigmentosa,rpe, retinal pigment epithelium,sms, sm synthase,sph, sphingosine,sphk, sphingosine kinase,s1pr, s1p receptor,spt, serine palmitoyl transferase,vegf, vascular endothelial growth factor,vmd, vitelliform macular dystrophy

                Comments

                Comment on this article